# HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/harmony-3-104-week-randomized-double-blind-placebo-and-active-controlled-trial/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Bo Åhrén,Susan Johnson,Murray Stewart,Deborah T. Cirkel,Fred Yang,Caroline Perry,Mark N. Feinglos |
| Citations | 227 |
| DOI | 10.2337/dc14-0024 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2019513002 |
| PMID | 24898304 |
| Type | article |
| Year | 2014 |

## Paper authors

- [Fred Yang](https://scholariq.org/researchers/fred-yang/)
- [Murray Stewart](https://scholariq.org/researchers/murray-stewart/)

## Paper journal

- [Diabetes Care](https://scholariq.org/journals/diabetes-care/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.